Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7638536 | AKARX INC | 2-Acylaminothiazole derivative or salt thereof |
May, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8765764 | AKARX INC | 2-acylaminothiazole derivative or salt thereof |
Jan, 2023
(22 days ago) | |
US8338429 | AKARX INC | 2-acylaminothiazole derivative or salt thereof |
Jun, 2023
(4 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 21, 2023 |
Orphan Drug Exclusivity (ODE) | Jun 26, 2026 |
New Indication (I) | Jun 26, 2022 |
NCE-1 date: May, 2022
Market Authorisation Date: 21 May, 2018
Treatment: Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure using doptelet; Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure; Treatment of thrombocytopenia in an adult patient with chronic immune thrombocytopenia who has had an insufficient response to a previous treatment
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic